Forest Laboratories has secured its first approval, in the US, for its injectable broad-spectrum cephalosporin antibiotic Teflaro (ceftaroline fosamil), for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA). Forest expects Teflaro to be available to wholesalers by January 2011.
"These are serious and potentially life-threatening infections for which new treatment options are needed," said Edward Cox, director of the office of antimicrobial products in FDA's Center for Drug Evaluation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?